Sentence examples for entry into trial from inspiring English sources

TNC levels at baseline (entry into trial) in four separate cohorts of RA patients were analysed by ELISA.

Median time from diagnosis to entry into trial was 77 days (range = 25 to 177 days), and in those with previous treatment, this was 247 days (range = 199 to 311 days).

Demographic data (gender, age, postal code), medical information (tumor site, number of prior chemotherapy regimens, performance status, referring physician), details of trial participation (trial entry date, trial entered, reasons for delayed entry into trial), and/or circumstances around trial non-entry were abstracted from physicians' clinical notes that were dictated after each clinic visit.

The analysis population included patients who consented to participate in Study 116, had microbiological evidence of MDR-TB prior to or at entry into Trial 204 (baseline), and had culture data using solid bacteriological media (e.g. Lowenstein Johnson or Ogawa medium) during participation in Study 116.

Our work, and that of others, would support inclusion of breast cancer patients in screening for entry into trials of vaccines against CTAGs.

17 Phase III randomised controlled trials are often too small and of too short a duration to detect small or cumulative adverse effects and are necessarily prescriptive in their choice of patients for entry into trials.

Inevitably, there will be a considerable number of women who will be identified as being resistant to conventional cytotoxics; these patients should be considered for entry into trials of new agents.

The use of prognostic models, as proposed from this analysis, may be important for discussing patient entry into trials and could, in future, be helpful as part of the inclusion criteria.

Cardiovascular magnetic resonance (CMR) offers a range of powerful imaging 3 and spectroscopic 4 techniques which can be used to identify suitable participants for entry into trials, to ensure baseline comparability of treatment arms and to generate markers of disease presence, severity or activity for use as outcome measures in clinical trials.

As a generalization, these clinic-based systems, although relatively good at quickly selecting low-risk patients who can be managed as outpatients, have not been particularly effective at identifying patients at highest risk who are most likely to benefit from entry into trials of novel therapies.

Randomization in randomized controlled trials is undertaken at entry into the trial, and since many trials concern major diseases arising in later life, many studies are of older persons.